BIOMAT Database Logo BIOMAT Database Logo

Amphotericin B is incompatible with lipid emulsions. 1996

O Ericsson, and A C Hallmen, and I Wikstrom

UI MeSH Term Description Entries
D004344 Drug Incompatibility The quality of not being miscible with another given substance without a chemical change. One drug is not of suitable composition to be combined or mixed with another agent or substance. The incompatibility usually results in an undesirable reaction, including chemical alteration or destruction. (Dorland, 27th ed; Stedman, 25th ed) Drug Incompatibilities,Incompatibilities, Drug,Incompatibility, Drug
D004655 Emulsions Colloids formed by the combination of two immiscible liquids such as oil and water. Lipid-in-water emulsions are usually liquid, like milk or lotion. Water-in-lipid emulsions tend to be creams. The formation of emulsions may be aided by amphiphatic molecules that surround one component of the system to form MICELLES. Emulsion
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics

Related Publications

O Ericsson, and A C Hallmen, and I Wikstrom
Comment: compatibility of amphotericin B with lipid emulsions.
December 1996, The Annals of pharmacotherapy,
O Ericsson, and A C Hallmen, and I Wikstrom
Serum pharmacology of amphotericin B applied in lipid emulsions.
April 1997, Antimicrobial agents and chemotherapy,
O Ericsson, and A C Hallmen, and I Wikstrom
[Amphotericin B into parenteral lipid emulsions. Galenic stability of mixtures. Preliminary results].
May 1996, Pathologie-biologie,
O Ericsson, and A C Hallmen, and I Wikstrom
The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures.
May 1997, The Journal of antimicrobial chemotherapy,
O Ericsson, and A C Hallmen, and I Wikstrom
Acrocyanosis developed with amphotericin B deoxycholate but not with amphotericin B lipid complex.
May 2007, Mycoses,
O Ericsson, and A C Hallmen, and I Wikstrom
[Amphotericin B--lipid complex].
January 1997, Enfermedades infecciosas y microbiologia clinica,
O Ericsson, and A C Hallmen, and I Wikstrom
Amphotericin B lipid complex.
October 1997, The Annals of pharmacotherapy,
O Ericsson, and A C Hallmen, and I Wikstrom
Nephrotoxicity of amphotericin B is attenuated by solubilizing with lipid emulsion.
September 1997, Journal of the American Society of Nephrology : JASN,
O Ericsson, and A C Hallmen, and I Wikstrom
Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia.
January 2000, The Cochrane database of systematic reviews,
O Ericsson, and A C Hallmen, and I Wikstrom
Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia.
September 2014, The Cochrane database of systematic reviews,
Copied contents to your clipboard!